Climb Bio director granted 40,000 stock options
Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock.
Rhea-AI Filing Summary
Climb Bio, Inc. reported that director Douglas E. Williams received a grant of stock options for 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. These options vest on the earlier of June 5, 2027 or immediately before the next annual meeting of stockholders, subject to his continued service. Following this grant, Williams holds 40,000 options directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 40,000 shares
Grant/Award
1 txn
Insider
WILLIAMS DOUGLAS E
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 40,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 40,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.
Key Figures
Options granted: 40,000 options
Exercise price: $10.55 per share
Expiration date: June 4, 2036
+1 more
4 metrics
Options granted
40,000 options
Stock Option (Right to Buy) grant to director
Exercise price
$10.55 per share
Strike price for option grant
Expiration date
June 4, 2036
Option term end date
Shares underlying options
40,000 shares
Common Stock underlying granted options
Key Terms
Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "10.5500""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-06-04T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
annual meeting of stockholders financial
"the date of the next annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Climb Bio (CLYM) report in this Form 4 filing?
Climb Bio disclosed that director Douglas E. Williams received a grant of 40,000 stock options. These options give him the right to buy common shares at a fixed price, representing standard equity-based director compensation rather than an open-market transaction.
How many Climb Bio (CLYM) stock options were granted to Douglas E. Williams?
Douglas E. Williams was granted 40,000 stock options. Each option relates to one share of Climb Bio common stock, creating potential future ownership if exercised according to the option terms once vesting conditions are satisfied.
What is the exercise price of the Climb Bio (CLYM) options granted?
The granted stock options have an exercise price of $10.55 per share. This means Williams can later buy Climb Bio common shares at $10.55, regardless of the market price at the time of exercise, once the options are vested.
When do Douglas E. Williams’ Climb Bio (CLYM) options vest?
The options vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders. Vesting is conditioned on Williams’ continued service with Climb Bio through that date, aligning incentives with ongoing board participation.
Are these Climb Bio (CLYM) transactions open-market buys or sales?
No, this Form 4 reflects a grant of stock options as compensation, not an open-market buy or sale. The options were awarded at no cost and become exercisable later, subject to vesting, rather than representing immediate trading activity in Climb Bio shares.
How many Climb Bio (CLYM) options does Williams hold after this grant?
After this grant, Williams holds 40,000 stock options in total, all from this award. These options are held directly and will remain a derivative position until he chooses to exercise them after they vest and before the June 4, 2036 expiration date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
